JMS-17-2

SKU: orb1301434

Description

JMS-17-2 is a highly potent and selective CX3CR1 antagonist with a sub-nanomolar IC50 of 0.32 nM. This small molecule inhibitor is a valuable research tool for investigating the role of the CX3CL1/CX3CR1 axis in neuroinflammation, atherosclerosis, and other disease models in both cellular and animal studies.

Research Area

Cell Biology, Immunology & Inflammation, Pharmacology & Drug Discovery

Key Properties

• CAS Number: 1380392-05-1
• MW: 419.95
• Purity: 99.44% (May vary between batches)
• Formula: C₂₅H₂₆ClN₃O
• SMILES: Clc1ccc(cc1)C1CCN(CCCn2c3ccccc3n3cccc3c2=O)CC1
• Target: CXCR
• Solubility: DMSO:11 mg/mL (26.19 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (4.76 mM)

Bioactivity

• Target IC50:
  CX3CR1:0.32 nM
• Animal Research:
  SKBR3 human breast cancer cells were serum starved for four hours before being exposed to 50nM recombinant human FKN for 5 minutes, with or without previous incubation with either a CX3CR1 neutralizing antibody used at 15μg/ml or the JMS-17-2 antagonist (10nM) for 30 minutes at 37 ℃.

Storage & Handling

• Storage: store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Inhibitor, GPR13, fractalkine receptor, JMS 17 2, JMS172, JMS-17-2, inhibit, CX3C chemokine receptor1, CX3CR1

Compound Identifiers

PubChem CID

57382073